Glaxosmithkline Biologicals

Glaxosmithkline Biologicals, registered as Smithkline Beecham Biologicals, is a foreign owned, for-profit corporate entity that provides vaccines and conducts vaccine research and development.

Through a $810,000 project grant from the National Institutes of Health National Institute of Allergy and Infectious Diseases, Glaxosmithkline Biologicals is developing two multivalent pan-Salmonella vaccines targeting Salmonella Paratyphi A, the bacteria that causes paratyphoid fever. Activities include preclinical studies, process development, manufacturing, and evaluation of immune responses to advance the vaccines toward clinical trials.

As a subcontractor under Trustees of Boston University, Glaxosmithkline Biologicals is formulating a trivalent Salmonella conjugate vaccine against invasive nontyphoidal Salmonellosis and typhoid fever for testing in Phase 1 trials, using its GMMA vaccine technology paired with a low-cost typhoid conjugate vaccine technology from Biological E Ltd. As another Boston University subcontractor, Glaxosmithkline Biologicals is conducting a Phase 1 trial of a Streptococcus vaccine to assess safety and immunogenicity. The goal is to develop a vaccine that reduces Strep A infections and sequelae like rheumatic heart disease, while also decreasing inappropriate antibiotic use that drives resistance.